Loading...
XLONDEMG
Market cap1mUSD
Dec 20, Last price  
0.08GBP
1D
0.00%
1Q
-30.43%
Jan 2017
-97.94%
Name

Deltex Medical Group PLC

Chart & Performance

D1W1MN
XLON:DEMG chart
P/E
P/S
85.41
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
20.16%
Rev. gr., 5y
-18.55%
Revenues
2m
-28.44%
2,494,0003,042,0003,511,0004,168,0005,235,0005,640,0006,279,0006,303,0006,777,0007,151,0006,507,0006,405,0006,331,0005,870,0004,955,0004,256,0002,398,0002,259,0002,482,0001,776,000
Net income
-1m
L+11.58%
-2,754,000-1,749,000-1,994,000-2,188,000-2,557,000-1,988,000-1,468,000-1,421,000-2,093,000-2,106,000-2,951,000-3,460,000-2,376,000-2,001,000-1,264,000-161,000-798,000-967,000-1,149,000-1,282,000
CFO
-1m
L+97.19%
-1,887,000-1,269,000-1,545,000-2,129,000-2,387,000-1,769,000-790,000-1,352,000-1,109,000-1,418,000-1,803,000-1,688,000-1,816,000-928,000-1,318,000609,000-68,000-291,000-606,000-1,195,000
Earnings
Mar 26, 2025

Profile

Deltex Medical Group plc, together with its subsidiaries, manufactures, markets, and sells oesophageal doppler haemodynamic monitoring systems under the TrueVue name in the United Kingdom, the United States, Spain, Canada, and internationally. It offers esophageal Doppler Probes that is used to measure a patient's central vascular blood flow and fluid status to measure real time blood velocities within the descending aorta; Loops plots aortic blood flow velocity and aortic blood pressure monitoring throughout every heartbeat; High Definition Impedance Cardiography, a non-invasive cardiac function and fluid status monitoring system for awake patients; and PressureWave, a pulse pressure waveform analysis algorithm used during periods of instability or for periods when the ODM mode is unavailable. The company also provides Deltex Medical Esophageal Doppler Simulator that enables clinicians to practice probe insertion, focusing, and waveform interpretation outside of a patient setting. Its products are used in Covid-19 critical care; sepsis; major abdominal, laparoscopic, and spinal surgeries; cardiac, trauma, and transplant procedures; and post-operative acute kidney injury monitoring. Deltex Medical Group plc was incorporated in 2000 and is headquartered in Chichester, the United Kingdom.
IPO date
Aug 20, 2001
Employees
44
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,776
-28.44%
2,482
9.87%
2,259
-5.80%
Cost of revenue
2,634
3,513
3,485
Unusual Expense (Income)
NOPBT
(858)
(1,031)
(1,226)
NOPBT Margin
Operating Taxes
(83)
(72)
(69)
Tax Rate
NOPAT
(775)
(959)
(1,157)
Net income
(1,282)
11.58%
(1,149)
18.82%
(967)
21.18%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,887
1,225
BB yield
-110.17%
-17.87%
Debt
Debt current
137
987
748
Long-term debt
1,961
1,246
1,256
Deferred revenue
Other long-term liabilities
71
241
285
Net debt
1,393
1,598
1,434
Cash flow
Cash from operating activities
(1,195)
(606)
(291)
CAPEX
(9)
(744)
(644)
Cash from investing activities
(370)
(744)
(644)
Cash from financing activities
1,786
1,413
502
FCF
(1,065)
(964)
(822)
Balance
Cash
705
471
413
Long term investments
164
157
Excess cash
616
511
457
Stockholders' equity
(32,507)
(31,444)
(31,600)
Invested Capital
37,642
35,811
35,394
ROIC
ROCE
EV
Common stock shares outstanding
1,181,215
685,491
580,712
Price
0.00
-85.50%
0.01
-29.82%
0.01
1.79%
Market cap
1,713
-75.01%
6,855
-17.16%
8,275
12.28%
EV
2,960
8,332
9,584
EBITDA
(725)
(903)
(1,112)
EV/EBITDA
Interest
230
199
173
Interest/NOPBT